State of the Commission’s negotiations with Novavax, Valneva and other COVID-19 vaccine manufacturers

27.4.2021

Question for written answer  E-002264/2021
to the Commission
Rule 138
Nicolás González Casares (S&D)

A few months ago, the Commission announced that it was in talks to conclude early purchase agreements with Novavax and Valneva, two COVID-19 vaccine manufacturers. I would like to know when the Commission will announce what agreement was reached concerning these contracts and, more importantly, if this time – contrary to what happened previously with other vaccine manufacturers – the Commission will make these contracts fully public.

Moreover, I would welcome an update on any exploratory talks with other promising vaccine developers, such as the vaccine designed by the Spanish National Council for Scientific Research (CSIC), which will be administered as a single intranasal dose and will probably prevent transmission of the virus.